ArticleAmerican journal of cancer research2024
Analysis of risk factors affecting the prognosis of angiosarcoma patients: a retrospective study.
Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatments and outcomes of primary and metastatic spinal angiosarcoma patients: study of 29 consecutive cases.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify prognostic factors influencing the survival of angiosarcoma patients and to explore the relationship between peripheral blood indicators and patient prognosis. A retrospective analysis was conducted on the clinical data collected from 105 angiosarcoma patients treated at China-Japan Union Hospital of Jilin University from January 2004 to April 2019, with an additional 50 patients included as external validation cohort. The median survival time for the study cohort was 1395 days, with 66.7% of patients (n=70) dying during the follow-up period. Significant differences were observed between the survival and death groups in age (P=0.022), primary tumor site (P=0.013), tumor size (P=0.008), and metastasis (P=0.018). Analysis of peripheral blood indicators showed that white blood cell (WBC) (P=0.006), platelet (PLT) (P=0.019), platelet-to-lymphocyte ratio (PLR) (P<0.001), and systemic immune-inflammation index (SII) (P=0.036) were significantly lower in the survival group, while lymphocyte (LYM) (P<0.001), albumin (ALB) (P<0.001), and prognostic nutritional index (PIN) (P<0.001) were significantly higher in the survival group. Multivariate Cox regression analysis identified SII (P=0.049, HR=0.551, 95% CI: 0.304-0.998), primary tumor site (P=0.001, HR=0.405, 95% CI: 0.235-0.699), metastasis (P=0.029, HR=1.864, 95% CI: 1.066-3.26), and chemotherapy (P=0.004, HR=0.434, 95% CI: 0.245-0.768) as independent prognostic factors affecting patients' 5-year survival. A nomogram model constructed based on these factors demonstrated high accuracy and stability in predicting 1-year, 3-year, and 5-year survival rates, with area under the curve (AUC) values of 0.836, 0.837, and 0.803, respectively, as validated by calibration curves and receiver operating characteristic (ROC) analysis. External validation further confirmed the model's reliability. Additionally, significant interactions were found between SII and primary tumor site (P=0.005) as well as chemotherapy (P=0.045). In conclusion, SII, primary tumor site, metastasis, and chemotherapy are crucial prognostic factors for angiosarcoma, and the developed nomogram provides a reliable tool for predicting survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.